Cipla shares fall as USFDA flags Greece plant in 2026

Why Cipla stock came under fresh selling pressure

Cipla Limited shares saw notable selling on Monday after the US Food and Drug Administration (USFDA) designated the company’s manufacturing facility in Greece as an official action indicated (OAI). The stock fell 2.4 percent to an intraday low of ₹1,309 per share on the National Stock Exchange (NSE). By 12:16 PM, Cipla was trading 1.52 percent lower at ₹1,320.7. In comparison, the Nifty 50 index was up 0.38 percent at the same time, highlighting the stock-specific nature of the move.

The development comes against the backdrop of recent volatility linked to Lanreotide Injection, one of Cipla’s top three products in the US market. Investors have been reacting to the risk of supply disruption after the USFDA flagged inspectional issues at a third-party manufacturing partner. Cipla has said manufacturing has been paused temporarily to support remediation efforts. The company has also indicated a timeline for re-supply.

What an OAI classification signals

An OAI status is used by the USFDA when inspection findings may warrant regulatory or administrative action. In this case, the OAI designation put focus back on manufacturing compliance and the pace of corrective actions at the Greece-linked site. For pharma companies with meaningful US exposure, such classifications can quickly affect market sentiment because they may influence supply continuity, product availability, and timelines for remediation.

Cipla’s stock reaction suggests the market is currently sensitive to compliance updates and inspection outcomes, especially when they relate to complex injectables supplied into the US market. While the article text does not quantify Cipla’s Lanreotide revenue contribution, it explicitly describes the product as one of Cipla’s top three in the US.

Lanreotide manufacturing pause and Cipla’s disclosure

Cipla previously disclosed that it temporarily paused manufacturing of Lanreotide Injection after supply disruptions linked to inspectional observations at a third-party partner. The partner was identified as Pharmathen International S.A. of Greece, described as the exclusive manufacturer and supplier for Lanreotide Injection to Cipla USA Inc.

According to Cipla’s exchange filing cited in the provided text, the manufacturing halt is meant to support remediation efforts addressing USFDA observations. Cipla also stated that re-supply is expected to resume in the first half of FY 2026–27. Until manufacturing restarts and receives quality clearance, Lanreotide will remain in limited supply. Cipla said it is monitoring supply levels and remains committed to restoring stable availability at the earliest.

What the USFDA found at Pharmathen’s Rodopi facility

The USFDA inspected Pharmathen’s Rodopi facility between November 10 and 21, 2025. The inspection resulted in nine Form 483 observations, as stated in the article text. A redacted version of the report was made public on January 7, 2026, which triggered media attention and added to volatility in Cipla’s share price.

Separately, the provided text also lists the nature of certain compliance gaps highlighted around the Lanreotide partner, including contamination-prevention procedures not being followed and deficient control systems to prevent contamination. Additional deficiencies mentioned include inadequate sterile conditions, laboratory deficiencies, manufacturing process failures, and poorly maintained buildings. These points were cited as weighing on investor sentiment.

Timeline of the key events cited

The sequence below captures the dated milestones explicitly stated in the provided text.

How Cipla shares moved: the numbers mentioned

Cipla’s stock move was described across multiple trading days and exchanges in the provided text. On Friday, the shares fell sharply after the Lanreotide update, and on Monday, the OAI classification kept the stock under pressure.

The text also notes Cipla’s total market capitalisation stood close to ₹1.1 lakh crore at the time referenced. It adds that the stock has tumbled more than 18 percent from its 52-week high of ₹1,673, which was hit nearly three months earlier.

What this means for supply and Cipla’s US product positioning

Cipla’s update indicates a practical near-term constraint: Lanreotide will remain in limited supply until production restarts and passes quality clearance. The company has communicated that re-supply is expected in the first half of FY 2026–27, which gives investors a specific, disclosed window to track.

Because Pharmathen is described as the exclusive manufacturer and supplier for Lanreotide Injection to Cipla USA Inc., the remediation timeline becomes central to the product’s supply continuity. The provided text does not mention alternate manufacturing arrangements, and a separate market note referenced in the text said the market was awaiting management commentary on alternate plans. Based only on what is stated, Cipla’s formal position is focused on remediation and monitoring supply levels.

Broader USFDA inspection context mentioned for Cipla

The provided text also references other USFDA-related updates involving Cipla facilities. It states that the USFDA classified an inspection at Cipla’s Patalganga, Maharashtra facility as Voluntary Action Indicated (VAI), following a routine cGMP inspection conducted on April 4, 2024. In that separate instance, the stock was noted as down 0.15 percent to ₹1,501 on the BSE.

Another referenced report says Cipla received six Form 483 observations for its manufacturing facility in Goa after an inspection conducted from June 10 to 21. On the NSE, Cipla stock declined as much as 3.02 percent during the day to ₹1,495.05, and was trading 1.79 percent lower at ₹1,513.90 at 11:09 a.m., while the Nifty was up 0.05 percent.

The text also includes Bloomberg analyst positioning: 25 of 38 analysts had a ‘buy’ rating, seven recommended ‘hold’, and six suggested ‘sell’.

What to watch next

The next key milestone is Cipla’s ability to normalise Lanreotide supply within the re-supply window it has communicated: the first half of FY 2026–27. Investors are likely to monitor any updates on remediation progress at the Pharmathen facility, the status of quality clearance, and whether supply constraints ease ahead of that timeframe.

For the stock, near-term movement may continue to respond to regulatory classifications and inspection updates, given the sensitivity seen after both the OAI designation and the earlier disclosure of manufacturing disruption. Any further exchange filings related to Lanreotide supply, inspection outcomes, or remediation timelines will remain central to market interpretation.